X4 Pharmaceuticals, Inc.
Address of Issuer’s Principal Executive
61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134
Name of Person Filing:
This statement is filed jointly by and on behalf of each of Ikarian
Capital, LLC, a Delaware limited liability company (“Ikarian
Capital”), and Neil Shahrestani (together referred herein
as the “Reporting Persons”). Ikarian Healthcare
Master Fund, L.P., a Cayman Islands exempted limited partnership
(the “Fund”), and certain separately managed accounts
managed by Ikarian Capital (collectively, the “Managed
Accounts”) are the record owners of the securities covered
by this statement. Ikarian Capital is an investment adviser
registered under the Investment Advisers Act of 1940, as amended,
and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts,
and may be deemed to have beneficial ownership of the securities
covered by this statement through the investment discretion it has
over the Fund and the Managed Accounts. Ikarian Capital is
ultimately controlled, indirectly, by Mr. Shahrestani.
Accordingly, Mr. Shahrestani may be deemed to indirectly
beneficially own securities beneficially owned by Ikarian Capital.
The Fund disclaims beneficial ownership of the shares held by the
Managed Accounts. The Managed Accounts disclaim beneficial
ownership of the shares held by the Fund.
Each Reporting Person declares that neither the filing of this
statement nor anything herein shall be construed as an admission
that such person is, for the purposes of Section 13(d) or
13(g) of the Act or any other purpose, the beneficial owner of any
securities covered by this statement.
Each Reporting Person may be deemed to be a member of a group with
respect to the issuer or securities of the issuer for the purpose
of Section 13(d) or 13(g) of the Act. Each of the Reporting
Persons declares that neither the filing of this statement nor
anything herein shall be construed as an admission that such person
is, for the purpose of Section 13(d) or 13(g) of the Act or
any other purpose, (i) acting (or has agreed or is agreeing to
act together with any other person) as a partnership, limited
partnership, syndicate, or other group for the purpose of
acquiring, holding, or disposing of securities of the issuer or
otherwise with respect to the issuer or any securities of the
issuer or (ii) a member of any group with respect to the
issuer or any securities of the issuer.
Address of Principal Business Office or, if None,
The address of the principal business office of each of the
Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court,
Suite 1620, Dallas, Texas 75201.
See Item 4 on the cover page(s) hereto.
Title and Class of Securities: